220
Participants
Start Date
November 28, 2022
Primary Completion Date
November 30, 2026
Study Completion Date
November 30, 2027
Abatacept (W12-W48)
"The experimental strategy will evaluate abatacept 125 mg/week following 12 weeks of anti-TNF prescribed in usual care. Concomitant treatment with stable doses of csDMARD, non-steroidal anti-inflammatory drugs, analgesic agents, glucocorticoids (≤10 mg of prednisone or the equivalent per day), or a combination of these drugs will be permitted.~Patients will continue to take methotrexate or leflunomide for the duration of the study."
TNF Inhibitor (W12-W48)
In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for 36 weeks. In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed.
TNF Inhibitor (W0-W12)
All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
RECRUITING
Centre Hospitalier Universitaire de Montpellier, Montpellier
RECRUITING
CHU Bordeaux groupe Pellegrin, Bordeaux
RECRUITING
CHU de Brest La Cavale Blanche, Brest
NOT_YET_RECRUITING
Centre Hospitalier de Cahors, Cahors
RECRUITING
CHD Vendée, La Roche-sur-Yon
RECRUITING
CH du Mans, Le Mans
RECRUITING
CHU de Nantes, Nantes
RECRUITING
CHU de Nice, Nice
NOT_YET_RECRUITING
CHU de Nîmes Carémeau, Nîmes
RECRUITING
CHR Orléans Nouvel hôpital d'Orléans, Orléans
NOT_YET_RECRUITING
APHP Bicêtre, Paris
RECRUITING
APHP Cochin, Paris
RECRUITING
APHP La Pitié Salpetrière, Paris
NOT_YET_RECRUITING
CHU de Strasbourg Hautepierre, Strasbourg
NOT_YET_RECRUITING
Chu Purpan, Toulouse
RECRUITING
CHU de Tours - Hopital Trousseau, Tours
RECRUITING
Centre hospitalier Princesse Grace, Monaco
University Hospital, Montpellier
OTHER